Inhibikase Therapeutics, Inc.IKTNASDAQ
Loading
Year-over-year free cash flow growth rate
Percentile
P13
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -90.03% |
| Q2 2025 | -35.84% |
| Q1 2025 | 23.24% |
| Q4 2024 | -9.52% |
| Q3 2024 | 3.43% |
| Q2 2024 | -30.70% |
| Q1 2024 | -12.33% |
| Q4 2023 | 16.14% |
| Q3 2023 | 10.36% |
| Q2 2023 | 23.32% |
| Q1 2023 | -67.93% |
| Q4 2022 | 37.66% |
| Q3 2022 | -29.69% |
| Q2 2022 | -11.81% |
| Q1 2022 | 3.95% |
| Q4 2021 | -102.71% |
| Q3 2021 | 52.42% |
| Q2 2021 | -7.94% |
| Q1 2021 | -315.65% |
| Q4 2020 | -1353.43% |
| Q3 2020 | 807.73% |
| Q2 2020 | 95.82% |
| Q1 2020 | -4108.03% |
| Q4 2019 | 193.71% |
| Q3 2019 | 86.16% |
| Q2 2019 | 82.98% |
| Q1 2019 | 0.00% |
| Q4 2018 | 0.00% |
| Q1 2018 | 0.00% |
| Q4 2017 | 0.00% |
| Q1 2017 | 0.00% |